Tuberculosis

Tuberculosis committee icon

The IMPAACT Tuberculosis Scientific Committee aims to evaluate novel approaches for TB prevention, diagnosis and treatment in infants, children, adolescents and pregnant and postpartum women with and without HIV that will lead to optimal dosing and regimens, licensing and decreased morbidity and mortality. 

 

 

 

 

Priorities include evaluation of:

  • Evaluate the efficacy, PK and safety of new and shorter drug regimens to prevent drug-susceptible and drug-resistant TB in infants, children, and adolescents and during pregnancy and postpartum, among populations living with and without HIV. 
  • Evaluate the efficacy, PK, safety and acceptability of new drug regimens, optimize existing drug dosing and evaluate novel drugs for the treatment of drug-susceptible and drug-resistant TB in infants, children, and adolescents and during pregnancy and postpartum, among populations living with and without HIV. 
  • Evaluate novel tools for the diagnosis of active TB, correlates of TB treatment in response and markers of disease progression in infants, children, and adolescents with and without HIV. 
  • Evaluate novel TB vaccines for prevention of TB disease. 

Learn more about the current portfolio and prior research from the Tuberculosis Scientific Committee. 

 

Committee Contacts

Chair: Anneke Hesseling
Vice Chair: Amita Gupta
Operations Center: Rachel Scheckter, Iris Mustich, and Stephanie Sivalingam

 

Presentations

Up Next:

The IMPAACT Brain and Mental Health Scientific Committee (formerly HIV Complications & Co-morbidities Scientific Committee) aims to determine optimal and feasible biological and behavioral methods for the prevention and management of neuropsychological and mental health complications of HIV and its treatment in infants, children, adolescents, and pregnant and postpartum people.